05:25 PM EDT, 05/13/2024 (MT Newswires) -- Theravance Biopharma ( TBPH ) Monday night reported a Q1 net loss of $0.24 per share, compared with $0.35 loss a year ago.

Analysts polled by Capital IQ expected $0.25 loss.

Revenue for the quarter ended March 31 was $14.5 million, up from $10.4 million a year earlier.

Analysts expected almost $14 million.

For 2024, the company said it continues to project a non-GAAP net loss for the first half of the year while approaching break-even on a non-GAAP basis during the second half.

Analysts polled by Capital IQ are looking for a $7.3 million non-GAAP loss this year.

Theravance shares were about 2% higher in after-hours trading.

Price: 9.77, Change: +0.19, Percent Change: +1.98